Literature DB >> 33877583

Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.

Lynsey Lakin1,2, Bryan E Davis2, Cherie C Binns3, Keisha M Currie4, Mary R Rensel5.   

Abstract

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system, leading to neurodegeneration and manifesting as a variety of symptoms. These can include "invisible" symptoms, not externally evident to others, such as fatigue, mood disorders, cognitive impairments, pain, bladder/bowel dysfunction, sexual dysfunction, and vision changes. Invisible symptoms are highly prevalent in people living with MS, with multifactorial etiology and potential to impact the disease course. Patient experiences of these symptoms include both physical and psychosocial elements, which when unaddressed negatively influence many aspects of quality of life and perception of health. Despite the high impact on patient lives, gaps persist in awareness and management of these hidden symptoms. The healthcare provider and patient author experiences brought together here serve to raise the profile of invisible symptoms and review strategies for a team-based approach to comprehensive MS care. We summarize the current literature regarding the prevalence and etiology of invisible symptoms to convey the high likelihood that a person living with MS will contend with one or more of these concerns. We then explore how open communication between people living with MS and their care team, stigma mitigation, and shared decision-making are key to comprehensive management of invisible symptoms. We recommend validated screening tools and technological advancements that may be incorporated into MS care to regularly monitor these symptoms, offering insight into how healthcare providers can both educate and listen to patients, with the goal of improved patient quality of life. By pairing clinical knowledge with an understanding and consideration of the patient perspective, providers will be equipped to foster a patient-centered dialogue that encourages shared decision-making. Invisible symptoms of MS.

Entities:  

Keywords:  Cognitive impairment; Fatigue; Invisible symptoms; Multiple sclerosis; Patient experience; Shared decision-making; Stigma

Year:  2021        PMID: 33877583     DOI: 10.1007/s40120-021-00239-2

Source DB:  PubMed          Journal:  Neurol Ther        ISSN: 2193-6536


  119 in total

1.  Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial.

Authors:  Amber Salter; Kaarina Kowalec; Kathryn C Fitzgerald; Gary Cutter; Ruth Ann Marrie
Journal:  Neurology       Date:  2020-06-17       Impact factor: 9.910

2.  Quality of life in patients with multiple sclerosis: the impact of fatigue and depression.

Authors:  Vallabh Janardhan; Rohit Bakshi
Journal:  J Neurol Sci       Date:  2002-12-15       Impact factor: 3.181

3.  Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis.

Authors:  Yavor Yalachkov; Dilara Soydaş; Johannes Bergmann; Stefan Frisch; Marion Behrens; Christian Foerch; Johannes Gehrig
Journal:  Mult Scler Relat Disord       Date:  2019-01-30       Impact factor: 4.339

4.  Severity of chronic pain and its relationship to quality of life in multiple sclerosis.

Authors:  Lorraine V Kalia; Paul W O'Connor
Journal:  Mult Scler       Date:  2005-06       Impact factor: 6.312

Review 5.  Multiple Sclerosis.

Authors:  Daniel S Reich; Claudia F Lucchinetti; Peter A Calabresi
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

6.  Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients.

Authors:  C J Archibald; P J McGrath; P G Ritvo; J D Fisk; V Bhan; C E Maxner; T J Murray
Journal:  Pain       Date:  1994-07       Impact factor: 6.961

7.  Invisible and visible symptoms of multiple sclerosis: which are more predictive of health distress?

Authors:  Carmel Parker White; Mark B White; Candyce S Russell
Journal:  J Neurosci Nurs       Date:  2008-04       Impact factor: 1.230

8.  Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning.

Authors:  S M Rao; G J Leo; L Ellington; T Nauertz; L Bernardin; F Unverzagt
Journal:  Neurology       Date:  1991-05       Impact factor: 9.910

9.  The notion of "invisibility" in people's experiences of the symptoms of multiple sclerosis: a systematic meta-synthesis.

Authors:  Le-Sharn Parker; Gogem Topcu; Danielle De Boos; Roshan das Nair
Journal:  Disabil Rehabil       Date:  2020-03-24       Impact factor: 3.033

10.  Which symptoms contribute the most to patients' perception of health in multiple sclerosis?

Authors:  Rivka Green; Gary Cutter; Michael Friendly; Ilya Kister
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-09-05
View more
  4 in total

Review 1.  MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression.

Authors:  Tjalf Ziemssen; Jo Vandercappellen; Valeria Jordan Mondragon; Gavin Giovannoni
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

2.  Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study.

Authors:  Laura Rosa; Maria Petracca; Antonio Carotenuto; Pasquale Dolce; Kyrie Piscopo; Francesca Dicé; Francesca Lauro; Antonio Luca Spiezia; Marcello Moccia; Luigi Lavorgna; Carmine Iacovazzo; Giuseppe Servillo; Nelson Mauro Maldonato; Alessandro Chiodi; Vincenzo Brescia Morra; Roberta Lanzillo
Journal:  J Clin Med       Date:  2022-09-04       Impact factor: 4.964

3.  A nurse-led, telephone-based patient support program for improving adherence in patients with relapsing-remitting multiple sclerosis using interferon beta-1a: Lessons from a consumer-based survey on adveva® PSP.

Authors:  Serena Barello; Damiano Paolicelli; Roberto Bergamaschi; Salvatore Cottone; Alessandra D'Amico; Viviana Annibali; Andrea Paolillo; Caterina Bosio; Valentina Panetta; Guendalina Graffigna
Journal:  Front Psychol       Date:  2022-08-24

4.  Assessment of factors associated with depression and anxiety among pwMS in Saudi Arabia.

Authors:  Safanah AlSaeed; Nuha M Alkhawajah; Mohsen Ayyash; Salman Aljarallah; Rola Alarieh; Amani Abu-Shaheen
Journal:  BMC Neurol       Date:  2022-03-25       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.